Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Oct 16, 2009

Premium

AnaSpec this week launched four phospho-specific anti-Tau antibodies.

In a statement, the company said that its collection of anti-Tau antibodies is now the industry's largest, consisting of 21 phospho-specific and 13 non-phospho-specific antibodies. The antibodies have been validated in dot blots and with immunohistochemistry.

Rabbit anti-phospho-Tau antibodies were raised against synthetic phosphopeptides and evaluated for specificity with ELISA and/or Western blot. Species reactivity includes human, mouse, and rat. Some antibodies have also shown reactivity with bovine, chicken, and zebrafish, the company said.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.